BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 16819331)

  • 1. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic role of claudins in serous effusions.
    Kleinberg L; Holth A; Fridman E; Schwartz I; Shih IeM; Davidson B
    Am J Clin Pathol; 2007 Jun; 127(6):928-37. PubMed ID: 17509990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
    Reich R; Vintman L; Nielsen S; Kaern J; Bedrossian C; Berner A; Davidson B
    Diagn Cytopathol; 2005 Nov; 33(5):332-7. PubMed ID: 16240397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
    J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.
    Davidson B; Xi Z; Saatcioglu F
    Diagn Cytopathol; 2007 Feb; 35(2):80-4. PubMed ID: 17230566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
    Hyun TS; Barnes M; Tabatabai ZL
    Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M; Hoogsteden HC; Van der Kwast TH
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
    Zhu W; Michael CW
    Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.
    Sigstad E; Dong HP; Nielsen S; Berner A; Davidson B; Risberg B
    Diagn Cytopathol; 2005 Nov; 33(5):325-31. PubMed ID: 16240402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications.
    Davidson B; Risberg B; Berner A; Nesland JM; Tropé CG; Kristensen GB; Bryne M; Goscinski M; van de Putte G; Flørenes VA
    Gynecol Oncol; 2001 Nov; 83(2):249-56. PubMed ID: 11606079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.